Allscripts' (MDRX) Veradigm Collaborates With Komodo Health
Zacks Investment Research | Aug 22, 2019 08:17AM ET
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) recently announced that its flagship Veradigm unit has entered into a long-term partnership with Komodo Health with a view to advance healthcare research. The collaboration is expected to help Veradigm investigate ways to reduce disease burden using an EHR (electronic health record) system. Notably, this fortifies Allscripts’ foothold in the global healthcare IT space.
For investors’ notice, San Francisco-based Komodo Health is a provider of live-saving therapies by improving standard of care, delivering care management and providing extensive research in patient data.
More on Veradigm
Introduced in 2018, Allscripts’ Veradigm integrated data systems and services business combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media.
Allscripts’ recent acquisition of the American College of Cardiology's cardiology and diabetes registry assets, which are expected to extend Veradigm's EHR-enabled ambulatory research network, is encouraging. Also, Veradigm has signed an agreement with WOMBA, which will utilize Veradigm’s eChart Courier to provide medical chart records for healthcare providers.
Allscripts now expects 2019 bookings within $1.5-$1.1 billion, reflecting strength in the Veradigm business.
Allscripts Strong on Developments
Allscripts has been witnessing a slew of developments in its EHR platform of late.
Earlier this month, Allscripts’ 2bPrecise partnered with Q-State Biosciences to combine 2bPrecise’s cloud-based platform with Q-State’s whole-genome and whole-exome sequencing capabilities. The collaboration is expected to benefit patients and care organizations through improved patient outcomes.
Last month, Allscripts announced its FollowMyHealth as a platform for existing Microsoft (NASDAQ:MSFT) HealthVault users to export their existing data and continue tracking their health online or through mobile apps on iOS and Android.
Price Performance
We believe the positive developments will boost the Zacks Rank #3 (Hold) stock, which has declined 35.8% compared with the .
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Intuitive Surgical’s long-term earnings growth rate is estimated at 13.3%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
It’s Illegal in 42 States, But Investors Will Make Billions Legally
In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year.
That’s twice as much as they spend on marijuana, legally or otherwise.
Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.